2009 NEWS RELEASES
November 2, 2009HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE POSITIVE RESULTS IN SECOND OF TWO PHASE 3 TRIALS OF BENLYSTA™ IN SYSTEMIC LUPUS ERYTHEMATOSUS
October 29, 2009HUMAN GENOME SCIENCES ANNOUNCES THIRD QUARTER 2009 FINANCIAL RESULTS AND KEY DEVELOPMENTS
October 20, 2009HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FULL PRESENTATION AT ACR OF POSITIVE PHASE 3 STUDY RESULTS FOR BENLYSTA™ IN SYSTEMIC LUPUS ERYTHEMATOSUS
October 19, 2009HUMAN GENOME SCIENCES ANNOUNCES $75 MILLION MILESTONE PAYMENT FOR ZALBIN™ PROGRESS
October 15, 2009HUMAN GENOME SCIENCES TO HOST NOVEMBER 2ND CONFERENCE CALL TO DISCUSS TOP-LINE RESULTS FROM SECOND PHASE 3 TRIAL OF BENLYSTA™ (BELIMUMAB) IN SYSTEMIC LUPUS ERYTHEMATOSUS
October 14, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT ANALYST & INVESTOR MEETING
October 1, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT JMP SECURITIES CONFERENCE
September 17, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT UBS CONFERENCE
September 10, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT MORGAN STANLEY CONFERENCE
September 8, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT ROBERT W. BAIRD CONFERENCE
September 4, 2009NOVEL EVIDENCE-BASED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RESPONDER INDEX DESCRIBED IN PEER REVIEWED PUBLICATION AS POTENTIALLY SIGNIFICANT ADVANCE IN LUPUS DRUG DEVELOPMENT
September 4, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT THOMAS WEISEL PARTNERS CONFERENCE
August 3, 2009HUMAN GENOME SCIENCES ANNOUNCES CLOSING OF PUBLIC OFFERING
July 28, 2009HUMAN GENOME SCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
July 27, 2009HUMAN GENOME SCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
July 22, 2009HUMAN GENOME SCIENCES ANNOUNCES SECOND-QUARTER 2009 FINANCIAL RESULTS AND KEY DEVELOPMENTS
July 22, 2009HUMAN GENOME SCIENCES ANNOUNCES NEW ORDER FOR RAXIBACUMAB (ABTHRAX™) FROM U.S. GOVERNMENT
July 20, 2009HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE POSITIVE PHASE 3 STUDY RESULTS FOR BENLYSTA™
July 20, 2009REMINDER - HUMAN GENOME SCIENCES TO HOST CONFERENCE CALL TO DISCUSS TOP-LINE PHASE 3 RESULTS FOR BENLYSTA™ (FORMERLY LYMPHOSTAT-B®) IN SYSTEMIC LUPUS ERYTHEMATOSUS
July 9, 2009DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAX
July 1, 2009HUMAN GENOME SCIENCES TO HOST JULY 20 CONFERENCE CALL TO DISCUSS TOP-LINE PHASE 3 RESULTS FOR BENLYSTA™ (FORMERLY LYMPHOSTAT-B®) IN SYSTEMIC LUPUS ERYTHEMATOSUS
June 19, 2009HUMAN GENOME SCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2B MONTHLY-DOSING TRIAL OF ALBUFERON®
June 19, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT PIPER JAFFRAY CONFERENCE
June 11, 2009HUMAN GENOME SCIENCES REPORTS POSITIVE LONG-TERM DATA FOR BENLYSTA™ (FORMERLY LYMPHOSTAT-B®) IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
June 8, 2009FYI FROM HUMAN GENOME SCIENCES: GLAXOSMITHKLINE STUDY SHOWS GSK’S NOVEL DIABETES TREATMENT SYNCRIA® (ALBIGLUTIDE) IMPROVES GLUCOSE CONTROL, REDUCES WEIGHT
May 21, 2009HUMAN GENOME SCIENCES SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR ABTHRAX™
May 7, 2009HUMAN GENOME SCIENCES AND NOVOZYMES ANNOUNCE AMENDMENT TO ALBUMIN FUSION LICENSE AGREEMENT
April 29, 2009HUMAN GENOME SCIENCES ANNOUNCES FIRST QUARTER 2009 FINANCIAL RESULTS AND KEY DEVELOPMENTS
April 25, 2009HUMAN GENOME SCIENCES REPORTS POSITIVE LATE-BREAKER RESULTS AT EASL FROM ACHIEVE PHASE 3 TRIALS OF ALBUFERON® IN PATIENTS WITH CHRONIC HEPATITIS C
April 22, 2009HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS FIRST QUARTER 2009 FINANCIAL RESULTS
March 27, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT CITI CONFERENCE
March 25, 2009HUMAN GENOME SCIENCES AND MORPHOTEK®, INC. ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTIBODIES FOR ONCOLOGY AND IMMUNOLOGY
March 13, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT COWEN CONFERENCE
March 9, 2009HUMAN GENOME SCIENCES ANNOUNCES POSITIVE RESULTS IN SECOND OF TWO PHASE 3 TRIALS OF ALBUFERON® IN CHRONIC HEPATITIS C
March 9, 2009HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL
February 26, 2009HUMAN GENOME SCIENCES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2008 FINANCIAL RESULTS AND KEY DEVELOPMENTS
February 18, 2009HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS FULL YEAR 2008 FINANCIAL RESULTS
February 17, 2009HUMAN GENOME SCIENCES TO RECEIVE $9 MILLION MILESTONE PAYMENT RELATED TO GLAXOSMITHKLINE INITIATION OF PHASE 3 CLINICAL TRIAL OF SYNCRIA® IN TYPE 2 DIABETES
February 2, 2009HUMAN GENOME SCIENCES BEGINS DELIVERY OF FIRST-IN-CLASS ANTHRAX TREATMENT TO U.S. STRATEGIC NATIONAL STOCKPILE
January 12, 2009HUMAN GENOME SCIENCES REPORTS SUBSTANTIAL PROGRESS TOWARD COMMERCIALIZATION AND ANNOUNCES 2009 GOALS AT JPMORGAN HEALTHCARE CONFERENCE
January 12, 2009HUMAN GENOME SCIENCES ANNOUNCES INITIATION OF PHASE 2B TRIAL OF ALBUFERON® DOSED MONTHLY IN CHRONIC HEPATITIS C
January 9, 2009HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT JPMORGAN CONFERENCE
